Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.
Thomas B AlexanderLei WangHiroto InabaBrandon M TriplettStanley B PoundsRaul C RibeiroChing-Hon PuiJeffrey E RubnitzPublished in: Cancer (2017)
The improved outcomes of the AML02 trial resulted from improved disease control for low-risk patients and overall decreased ED/TRM. These results emphasize the importance of supportive-care measures throughout chemotherapy courses and hematopoietic cell transplantation and the value of treatment intensity for patients with low-risk AML while underscoring the need for novel therapy, rather than increased therapy intensity, for children with high-risk AML. Cancer 2017;123:3791-3798. © 2017 American Cancer Society.
Keyphrases
- acute myeloid leukemia
- clinical trial
- allogeneic hematopoietic stem cell transplantation
- papillary thyroid
- healthcare
- emergency department
- newly diagnosed
- ejection fraction
- squamous cell
- palliative care
- high intensity
- young adults
- randomized controlled trial
- phase ii
- stem cells
- metabolic syndrome
- childhood cancer
- radiation therapy
- adipose tissue
- lymph node metastasis
- study protocol
- coronary artery disease
- patient reported outcomes
- skeletal muscle
- mesenchymal stem cells
- cell therapy
- insulin resistance
- bone marrow